XML 12 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover - shares
 9 Months Ended
Mar. 31, 2024
May 10, 2024
Cover [Abstract]    
Document Type 10-Q/A  
Amendment Flag true  
Amendment Description Renovaro Inc. (the “Company”, “we”, “our”, or “us”) is filing this Amendment No. 2 to its Quarterly Report on Form 10-Q/A (this “Amendment”) to amend its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2024, as amended by that Form 10-Q/A filed with the SEC on August 20, 2024, (the “Q3 2024 Form 10-Q”) to (i) restate its financial statements as of and for the periods ended March 31, 2024, which should no longer be relied on and are being restated herein; and (ii) describe the restatement and its impact on previously reported amounts.   We are filing this Amendment to amend and restate the Q3 2024 Form 10-Q with modifications as necessary to reflect these restatements.   Background of Restatement   On February 18, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company, based on the recommendation of the Company’s management, and after consultation with the Company’s independent registered public accounting firm, concluded that the Company’s previously issued unaudited interim condensed consolidated financial statements for the quarter ended March 31, 2024 contained a material misstatement related to certain warrants which were exercised during the three months ended March 31, 2024, which had not been appropriately reflected as a component of the change in fair value of the contingent consideration during the three and nine months ended March 31, 2024. Accordingly, those financial statements should no longer be relied upon. Similarly, related reports filed with the Securities Exchange Commission (the “SEC”), earnings releases, press releases, shareholder communications, investor presentations or other communications describing relevant portions of the March 31, 2024, financial statements should no longer be relied upon. The Company is restating the March 31, 2024, financial statements within this Amendment.    Refer to “Note 2 - Restatement of Previously Issued Financial Statements” of “Part I - Item 1. Financial Statements” (“Note 2”) for additional information.   Internal Control Considerations   Due to discovery of the error, the Company’s management re-evaluated the effectiveness of the Company’s internal control over financial reporting (“ICFR”) as of March 31, 2024 and believes the error relates to and is the result of a previously identified and reported material weakness which has been disclosed in our Form 10-K filed on October 2, 2023. The material weakness remained in place as of March 31, 2024. For a discussion of management’s consideration of disclosure controls and procedures, internal controls over financial reporting and the material weaknesses identified, see “Part I - Item 4. Controls and Procedures” of this Amendment.   Items Amended in this Amendment   This Amendment amends and restates the following items included in the original filing as appropriate to reflect the restatement of the relevant periods:   ●Part I - Item 1. Financial Statements (Unaudited);   ●Part I - Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and   ●Part II, Item 6. Exhibits.   This Amendment includes new certifications by our principal executive officer and principal financial officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 dated as of this filing in connection with this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2 hereto.   Except as described in Note 2, no other information included in the Q3 2024 Form 10-Q is being amended or updated by this Amendment and, other than as described herein, this Amendment does not purport to reflect any information or events subsequent to the Q3 2024 Form 10-Q. This Amendment continues to describe the conditions as of the date of the Q3 2024 Form 10-Q and, except as expressly contained herein, we have not updated, modified or supplemented the disclosures contained in the Q3 2024 Form 10-Q. Accordingly, this Amendment should be read in conjunction with the Q3 2024 Form 10-Q and with our filings with the SEC subsequent to the Q3 2024 Form 10-Q.  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2024  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --06-30  
Entity File Number 001-38758  
Entity Registrant Name Renovaro Inc.  
Entity Central Index Key 0001527728  
Entity Tax Identification Number 45-2559340  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 2080 Century Park East  
Entity Address, Address Line Two Suite 906  
Entity Address, City or Town  Los Angeles  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 90067  
City Area Code 305  
Local Phone Number 918-1980  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol RENB  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   147,504,944